CADPS

Summary

CADPS (calcium dependent secretion activator, HGNC:1426) is a protein-coding gene on chromosome 3p14.2, encoding Calcium-dependent secretion activator 1 (Q9ULU8). Calcium-binding protein involved in exocytosis of vesicles filled with neurotransmitters and neuropeptides.

This gene encodes a novel neural/endocrine-specific cytosolic and peripheral membrane protein required for the Ca2+-regulated exocytosis of secretory vesicles. The protein acts at a stage in exocytosis that follows ATP-dependent priming, which involves the essential synthesis of phosphatidylinositol 4,5-bisphosphate (PtdIns(4,5)P2). Alternative splicing has been observed at this locus and three variants, encoding distinct isoforms, are described.

Source: NCBI Gene 8618 — RefSeq curated summary.

At a glance

• GWAS associations: 30
• Clinical variants (ClinVar): 204 total — 1 likely-pathogenic
• MANE Select transcript: NM_003716

Identifiers

Gene identifiers

Field	Value
HGNC ID	HGNC:1426
Approved symbol	CADPS
Name	calcium dependent secretion activator
Location	3p14.2
Locus type	gene with protein product
Status	Approved
Aliases	CAPS, KIAA1121, CAPS1, UNC-31, CADPS1
Ensembl gene	ENSG00000163618
Ensembl biotype	protein_coding
OMIM	604667
Entrez	8618

Gene structure

Transcript identifiers

Ensembl transcripts: 25 — 16 protein_coding, 7 retained_intron, 2 protein_coding_CDS_not_defined

ENST00000283269, ENST00000357948, ENST00000383710, ENST00000462768, ENST00000463002, ENST00000466621, ENST00000468271, ENST00000469292, ENST00000473635, ENST00000474560, ENST00000478408, ENST00000478434, ENST00000478570, ENST00000486172, ENST00000490353, ENST00000490424, ENST00000491424, ENST00000542833, ENST00000612439, ENST00000935174, ENST00000951692, ENST00000951693, ENST00000951694, ENST00000951695, ENST00000951696

RefSeq mRNA: 3 — MANE Select: NM_003716 NM_003716, NM_183393, NM_183394

CCDS: CCDS2898, CCDS2899, CCDS46858

Canonical transcript exons

ENST00000383710 — 30 exons

Exon	Start	End
ENSE00001076605	62438104	62438211
ENSE00001076644	62516580	62516643
ENSE00001256365	62536445	62536581
ENSE00001256496	62592637	62592748
ENSE00001256652	62650847	62651080
ENSE00001256674	62765871	62765984
ENSE00001343731	62499162	62499268
ENSE00001343741	62549903	62550115
ENSE00001343746	62570872	62570938
ENSE00001343748	62585185	62585324
ENSE00001343752	62645722	62645843
ENSE00001343758	62753441	62753773
ENSE00001409551	62532871	62533058
ENSE00001498232	62481723	62481869
ENSE00001498233	62493645	62493665
ENSE00002236851	62874589	62875416
ENSE00002314502	62445765	62445797
ENSE00002336454	62518149	62518250
ENSE00002368455	62557405	62557513
ENSE00002397916	62516059	62516182
ENSE00002404962	62662314	62662394
ENSE00002409408	62512751	62512768
ENSE00003474363	62403081	62403185
ENSE00003476361	62492290	62492446
ENSE00003480325	62398348	62399585
ENSE00003483629	62478261	62478416
ENSE00003496834	62466339	62466413
ENSE00003609118	62474173	62474320
ENSE00003669388	62465367	62465450
ENSE00003786871	62491339	62491480

Expression profiles

Bgee: expression breadth ubiquitous, 201 present calls, max score 97.91.

FANTOM5 (CAGE): breadth broad, TPM avg 7.8378 / max 258.8939, expressed in 524 samples.

FANTOM5 promoters (6 alternative TSS)

Promoter ID	TPM avg	Samples expressed
42820	6.4342	484
42819	0.5132	185
42816	0.5109	207
42821	0.1323	84
42818	0.1317	86
42817	0.1154	69

Top tissues by expression

258 total, by Bgee expression score (0-100, higher = more expressed):

Tissue	Anatomy ID	Expression score	Quality
pons	UBERON:0000988	97.91	gold quality
cortical plate	UBERON:0005343	97.87	gold quality
Brodmann (1909) area 46	UBERON:0006483	97.74	gold quality
prefrontal cortex	UBERON:0000451	97.21	gold quality
Brodmann (1909) area 9	UBERON:0013540	97.08	gold quality
dorsolateral prefrontal cortex	UBERON:0009834	96.79	gold quality
cerebellar cortex	UBERON:0002129	96.15	gold quality
cerebellar hemisphere	UBERON:0002245	96.13	gold quality
frontal cortex	UBERON:0001870	96.08	gold quality
right hemisphere of cerebellum	UBERON:0014890	95.80	gold quality
cerebellum	UBERON:0002037	95.70	gold quality
neocortex	UBERON:0001950	95.65	gold quality
cerebral cortex	UBERON:0000956	95.55	gold quality
right frontal lobe	UBERON:0002810	95.49	gold quality
superior frontal gyrus	UBERON:0002661	95.48	gold quality
postcentral gyrus	UBERON:0002581	95.35	gold quality
islet of Langerhans	UBERON:0000006	95.32	gold quality
hypothalamus	UBERON:0001898	95.14	gold quality
anterior cingulate cortex	UBERON:0009835	95.11	gold quality
middle temporal gyrus	UBERON:0002771	94.97	gold quality
pituitary gland	UBERON:0000007	94.85	gold quality
Brodmann (1909) area 10	UBERON:0013541	94.79	gold quality
Ammon’s horn	UBERON:0001954	94.53	gold quality
primary visual cortex	UBERON:0002436	94.34	gold quality
parietal lobe	UBERON:0001872	94.33	gold quality
buccal mucosa cell	CL:0002336	93.98	gold quality
brain	UBERON:0000955	93.98	gold quality
lateral nuclear group of thalamus	UBERON:0002736	93.98	gold quality
Brodmann (1909) area 23	UBERON:0013554	93.91	gold quality
forebrain	UBERON:0001890	93.87	gold quality

Single-cell (SCXA)

Detected in 12 experiment(s), a significant marker in 12.

Experiment	Marker?	Max mean expression
E-MTAB-11268	yes	2016.74
E-GEOD-180759	yes	1906.73
E-MTAB-7316	yes	1713.44
E-MTAB-11121	yes	1633.94
E-GEOD-137537	yes	1386.82
E-HCAD-25	yes	1296.03
E-HCAD-35	yes	1210.32
E-MTAB-5061	yes	13.57
E-ANND-3	yes	9.07
E-GEOD-125970	yes	6.91
E-CURD-46	yes	4.74
E-GEOD-83139	yes	4.01

Regulation

Is transcription factor: no

miRNA regulators (miRDB)

96 targeting CADPS, top 30 by miRDB confidence (max_score; target_count = how many genes the miRNA targets in total — lower means more specific):

miRNA	Max score	Avg score	miRNA target_count
HSA-MIR-30A-5P	100.00	76.31	3233
HSA-MIR-30B-5P	100.00	76.29	3248
HSA-MIR-30C-5P	100.00	76.29	3248
HSA-MIR-30D-5P	100.00	76.32	3233
HSA-MIR-30E-5P	100.00	76.32	3242
HSA-MIR-3163	100.00	77.23	8605
HSA-MIR-1252-5P	100.00	69.80	2774
HSA-MIR-3613-3P	100.00	76.36	7965
HSA-MIR-340-5P	100.00	72.50	4437
HSA-MIR-5692A	100.00	74.40	6850
HSA-MIR-3662	99.99	73.82	5684
HSA-MIR-186-5P	99.99	70.83	3707
HSA-MIR-1184	99.99	68.19	1458
HSA-MIR-548P	99.98	72.25	3784
HSA-MIR-3692-3P	99.98	70.27	2139
HSA-MIR-4775	99.98	75.00	6394
HSA-MIR-5696	99.98	72.36	4487
HSA-MIR-1468-3P	99.96	72.74	3797
HSA-MIR-493-5P	99.96	72.47	2382
HSA-MIR-1250-3P	99.96	70.04	4038
HSA-MIR-548AT-5P	99.96	70.83	2666
HSA-MIR-3910	99.95	71.13	2227
HSA-MIR-651-3P	99.94	73.48	5177
HSA-MIR-10527-5P	99.91	72.28	3754
HSA-MIR-548E-5P	99.89	72.73	4486
HSA-MIR-153-5P	99.89	73.86	6317
HSA-MIR-124-3P	99.89	73.74	3043
HSA-MIR-506-3P	99.89	73.55	3057
HSA-MIR-4302	99.89	67.94	1187
HSA-MIR-137-3P	99.87	74.74	2401

Literature-anchored findings (GeneRIF, showing 8)

• Regulation of dense core vesicle release from PC12 cells by interaction between the D2 dopamine receptor and calcium-dependent activator protein for secretion (CAPS). (PMID:15857609)
• Increased level of CADPS protein, human in Schizophrenic patients (PMID:21601610)
• Loss of CADPS is associated with central nervous system primitive neuroectodermal tumor. (PMID:21798848)
• the preferential binding of CAPS1 to open syntaxin-1 can contribute to the stabilization of the open state of syntaxin-1 during its transition from “closed” state to the SNARE complex formation. (PMID:23801330)
• CAPS1 promotes colorectal cancer metastasis through PI3K/Akt/GSK3beta/Snail signal pathway-mediated epithelial mesenchymal transformation process (PMID:30742066)
• CAPS1 Suppresses Tumorigenesis in Cholangiocarcinoma. (PMID:31562609)
• Study revealed that CAPS1 promoted normal colonic epithelial FHC cells migration by altering the protein expression profile of exosomes derived from colorectal cancer cells cells. GW4869, an exosome inhibitor, inhibited CAPS1-induced cell migration. (PMID:31638236)
• CADPS functional mutations in patients with bipolar disorder increase the sensitivity to stress. (PMID:35169262)

Cross-species orthologs

0 orthologs

Protein

Protein identifiers

Calcium-dependent secretion activator 1 — Q9ULU8 (reviewed: Q9ULU8)

Alternative names: Calcium-dependent activator protein for secretion 1

All UniProt accessions (7): Q9ULU8, F1T0E5, H0YFP0, H7C4K9, H7C4P2, H7C4T6, H7C538

UniProt curated annotations — full annotation on UniProt →

Function. Calcium-binding protein involved in exocytosis of vesicles filled with neurotransmitters and neuropeptides. Probably acts upstream of fusion in the biogenesis or maintenance of mature secretory vesicles. Regulates catecholamine loading of DCVs. May specifically mediate the Ca(2+)-dependent exocytosis of large dense-core vesicles (DCVs) and other dense-core vesicles by acting as a PtdIns(4,5)P2-binding protein that acts at prefusion step following ATP-dependent priming and participates in DCVs-membrane fusion. However, it may also participate in small clear synaptic vesicles (SVs) exocytosis and it is unclear whether its function is related to Ca(2+) triggering.

Subunit / interactions. Homodimer. Interacts with RASL10B. Interacts with the dopamine receptor DRD2.

Subcellular location. Synapse. Cytoplasmic vesicle. Secretory vesicle. Neuronal dense core vesicle membrane.

Tissue specificity. Specifically expressed in neural and endocrine secretory tissues. Expressed in brain and pancreas and at low level in heart. Also expressed in fetal heart, cerebellum, cerebral cortex, medulla, occipital pole, frontal and temporal lobes, and putamen, as well as weak expression in spinal cord.

Domain organisation. The PH domain is essential for regulated exocytosis and binds phospholipids and plasma membrane. It however does not mediate binding to DCVs.

Isoforms (5)

UniProt ID	Names	Canonical?
Q9ULU8-1	1	yes
Q9ULU8-2	2
Q9ULU8-3	3
Q9ULU8-4	4
Q9ULU8-5	5

RefSeq proteins (3): NP_003707, NP_899630, NP_899631 (=MANE)

Domains & families (InterPro)

ID	Name	Type
IPR000008	C2_dom	Domain
IPR001849	PH_domain	Domain
IPR010439	MUN_dom	Domain
IPR011993	PH-like_dom_sf	Homologous_superfamily
IPR014770	Munc13_1	Domain
IPR033227	CAPS	Family
IPR057457	CAPS_C2	Domain

Pfam: PF00169, PF06292, PF25341

UniProt features (40 total): strand 9, splice variant 8, sequence conflict 7, modified residue 4, region of interest 4, domain 3, compositionally biased region 3, chain 1, helix 1

Structure

Experimental structures (PDB)

1 structures.

PDB	Method	Resolution (Å)
1WI1	SOLUTION NMR

Predicted structure (AlphaFold)

Model	pLDDT	Fraction very-high
AF-Q9ULU8-F1	79.13	0.43

Functional residue map

Curated UniProt residues grouped by drug-discovery relevance — catalytic, ligand-binding, modification, and mutation-validated positions. Source: UniProtKB sequence features.

Post-translational modifications (4): 34, 91, 98, 261

Function

Pathways and Gene Ontology

Reactome pathways

0 pathways

MSigDB gene sets: 293 (showing top): AAGCAAT_MIR137, GOBP_VESICLE_LOCALIZATION, GOCC_SECRETORY_GRANULE, GCANCTGNY_MYOD_Q6, KAAB_HEART_ATRIUM_VS_VENTRICLE_UP, MODULE_563, GOBP_REGULATION_OF_EXOCYTOSIS, GOBP_NEUROTRANSMITTER_TRANSPORT, AP4_Q6, CERVERA_SDHB_TARGETS_1_DN, GOBP_VESICLE_MEDIATED_TRANSPORT, FOXO4_01, FOXO1_01, CHANDRAN_METASTASIS_DN, CAGCTG_AP4_Q5

GO Biological Process (5): exocytosis (GO:0006887), protein transport (GO:0015031), synaptic vesicle exocytosis (GO:0016079), positive regulation of exocytosis (GO:0045921), dense core granule exocytosis (GO:1990504)

GO Molecular Function (4): lipid binding (GO:0008289), protein kinase binding (GO:0019901), metal ion binding (GO:0046872), protein binding (GO:0005515)

GO Cellular Component (9): cytosol (GO:0005829), presynapse (GO:0098793), glutamatergic synapse (GO:0098978), neuronal dense core vesicle membrane (GO:0099012), endomembrane system (GO:0012505), membrane (GO:0016020), cytoplasmic vesicle membrane (GO:0030659), cytoplasmic vesicle (GO:0031410), synapse (GO:0045202)

GO top-level categories

Rollup of top GO terms by namespace:

Category	Terms
cellular anatomical structure	4
binding	2
cytoplasm	2
synapse	2
vesicle-mediated transport	1
secretion by cell	1
vesicle fusion to plasma membrane	1
transport	1
intracellular protein localization	1
establishment of protein localization	1
neurotransmitter secretion	1
regulated exocytosis	1
establishment of localization in cell	1
presynapse	1
vesicle-mediated transport in synapse	1
synaptic vesicle cycle	1
signal release from synapse	1
exocytosis	1
regulation of exocytosis	1
positive regulation of secretion by cell	1
calcium-ion regulated exocytosis	1
dense core granule localization	1
establishment of vesicle localization	1
kinase binding	1
cation binding	1
dense core granule membrane	1
neuronal dense core vesicle	1
vacuole	1
plasma membrane	1
vesicle membrane	1
cytoplasmic vesicle	1
intracellular vesicle	1
cell junction	1

Protein interactions and networks

STRING

1524 interactions, top by confidence (×1000):

Protein A	Protein B	Partner UniProt	Score
CADPS	UNC13B	O14795	826
CADPS	RASL10B	Q96S79	826
CADPS	PI4KB	P78405	814
CADPS	NCS1	P36610	789
CADPS	POM121	Q96HA1	747
CADPS	KCND1	Q9NSA2	649
CADPS	VSNL1	P28677	649
CADPS	IL1RAPL1	Q9NZN1	636
CADPS	STXBP1	P61764	572
CADPS	KCNC1	P48547	570
CADPS	IGDCC3	Q8IVU1	570
CADPS	KCND2	Q9NZV8	561
CADPS	RCVRN	P35243	542
CADPS	UNC119	Q13432	522
CADPS	STXBP5	Q5T5C0	501

IntAct

21 interactions, top by confidence:

A	B	Type	Score
CHMP2B	CADPS	psi-mi:“MI:0915”(physical association)	0.400
CADPS	TCL1A	psi-mi:“MI:0915”(physical association)	0.370
KIAA1549	CADPS	psi-mi:“MI:0915”(physical association)	0.370
CADPS		psi-mi:“MI:0915”(physical association)	0.370
NEK4	E2F8	psi-mi:“MI:0914”(association)	0.350
PRNP	CARNS1	psi-mi:“MI:0914”(association)	0.350
MAPT	SHTN1	psi-mi:“MI:0914”(association)	0.350
GPM6A	KIF2A	psi-mi:“MI:0914”(association)	0.350
CADPS	ACOT7	psi-mi:“MI:0914”(association)	0.350
CADPS	CLIP1	psi-mi:“MI:0914”(association)	0.350
KLHL22	TRAV18	psi-mi:“MI:0914”(association)	0.350
VCP	FAM171A2	psi-mi:“MI:0914”(association)	0.350
DNAJC5	CADPS	psi-mi:“MI:2364”(proximity)	0.270
DISC1	CADPS	psi-mi:“MI:0915”(physical association)	0.000
EXOC1	CADPS	psi-mi:“MI:0915”(physical association)	0.000
TTC3	CADPS	psi-mi:“MI:0915”(physical association)	0.000
DSCAM	CADPS	psi-mi:“MI:0915”(physical association)	0.000
CADPS	LUC7L2	psi-mi:“MI:0915”(physical association)	0.000
PIP5K1A	CADPS	psi-mi:“MI:0915”(physical association)	0.000

BioGRID (69): CADPS (Two-hybrid), CADPS (Two-hybrid), C19orf66 (Two-hybrid), FAM161A (Two-hybrid), ZNF572 (Two-hybrid), FAM9B (Two-hybrid), TTLL10 (Two-hybrid), C17orf67 (Two-hybrid), CLIP1 (Affinity Capture-MS), CLIP1 (Affinity Capture-MS), CADPS (Two-hybrid), DNAJC5 (FRET), CADPS (Two-hybrid), CADPS (Two-hybrid), CADPS (Two-hybrid)

ESM2 similar proteins: A0A5F9C6I2, A1L3F5, A2BDA5, A3KGS3, A8E4X8, D3ZXK7, F1R7R1, O75129, P21359, P51593, P97526, Q04690, Q1JPG0, Q2PPJ7, Q3SZD5, Q4QQM5, Q4R5A4, Q5RC14, Q5XPI3, Q5XPI4, Q62717, Q66K64, Q6GLR7, Q6NXD8, Q6P4S8, Q6PFH3, Q6VNB8, Q7L4E1, Q7TMY8, Q7Z6Z7, Q80TJ1, Q86UW7, Q8BHR8, Q8BK03, Q8BYR5, Q8CDG3, Q8CF97, Q8CID0, Q8IY22, Q8IZQ1

Diamond homologs: Q23658, Q60PC0, Q62717, Q6GLR7, Q80TJ1, Q86UW7, Q8BYR5, Q9NHE5, Q9ULU8

SIGNOR signaling

4 interactions.

A	Effect	B	Mechanism
“phosphatidylinositol bisphosphate”	“up-regulates activity”	CADPS	“chemical activation”
CADPS	“up-regulates activity”	STX1A	binding
CADPS	“up-regulates activity”	SNAP25	binding
CADPS	“up-regulates activity”	VAMP2	binding

Disease & clinical

Clinical variants and AI predictions

ClinVar

204 variants total. Per-class counts are floors (≥ shown; pagination cap):

Classification	Count (floor)
Pathogenic	0
Likely pathogenic	1
Uncertain significance	150
Likely benign	31
Benign	5

Top pathogenic / likely-pathogenic (1)

Variant ID	HGVS	Classification
442399	GRCh37/hg19 3p14.2-14.1(chr3:60526226-63742930)x1	Likely pathogenic

SpliceAI

7305 predictions. Top by Δscore:

Variant	Effect	Δscore
19:5914383:A:AG	acceptor_gain	1.0000
19:5914383:AGCT:A	acceptor_gain	1.0000
19:5914384:G:GA	acceptor_gain	1.0000
19:5914384:GC:G	acceptor_gain	1.0000
19:5914384:GCT:G	acceptor_gain	1.0000
19:5914384:GCTG:G	acceptor_gain	1.0000
19:5914384:GCTGC:G	acceptor_gain	1.0000
19:5914486:CCAGG:C	donor_loss	1.0000
19:5914487:CAGG:C	donor_loss	1.0000
19:5914488:AGGTG:A	donor_loss	1.0000
19:5914489:GGTG:G	donor_loss	1.0000
19:5914490:GTG:G	donor_loss	1.0000
19:5914491:T:A	donor_loss	1.0000
19:5914680:G:GT	donor_gain	1.0000
19:5915134:G:GT	donor_gain	1.0000
19:5915138:G:GT	donor_gain	1.0000
3:62399581:GTTTT:G	acceptor_gain	1.0000
3:62399582:TTTT:T	acceptor_gain	1.0000
3:62399583:TTT:T	acceptor_gain	1.0000
3:62399584:TT:T	acceptor_gain	1.0000
3:62399586:C:CC	acceptor_gain	1.0000
3:62399587:T:C	acceptor_loss	1.0000
3:62438098:ACT:A	donor_loss	1.0000
3:62438099:CTT:C	donor_loss	1.0000
3:62438100:TTACA:T	donor_loss	1.0000
3:62438101:TAC:T	donor_loss	1.0000
3:62438102:A:AC	donor_gain	1.0000
3:62438102:A:C	donor_loss	1.0000
3:62438102:ACAT:A	donor_gain	1.0000
3:62438103:C:CG	donor_gain	1.0000

AlphaMissense

8965 scored. Top likely-pathogenic:

Variant	Protein change	am_pathogenicity
3:62478343:A:G	W1083R	1.000
3:62478343:A:T	W1083R	1.000
3:62491352:A:G	W1005R	1.000
3:62491352:A:T	W1005R	1.000
3:62491405:A:G	L987P	1.000
3:62492341:A:G	W945R	1.000
3:62492341:A:T	W945R	1.000
3:62516590:A:G	L816P	1.000
3:62518149:C:A	R798M	1.000
3:62532877:C:T	G762E	1.000
3:62532887:G:C	H759D	1.000
3:62532897:G:C	F755L	1.000
3:62532897:G:T	F755L	1.000
3:62532898:A:G	F755S	1.000
3:62532899:A:G	F755L	1.000
3:62532901:G:T	A754D	1.000
3:62532906:G:C	S752R	1.000
3:62532906:G:T	S752R	1.000
3:62532908:T:G	S752R	1.000
3:62532914:G:C	H750D	1.000
3:62533042:C:T	G707D	1.000
3:62533043:C:G	G707R	1.000
3:62533045:G:T	P706H	1.000
3:62533047:A:C	S705R	1.000
3:62533047:A:T	S705R	1.000
3:62533049:T:G	S705R	1.000
3:62533055:A:G	W703R	1.000
3:62533055:A:T	W703R	1.000
3:62533057:C:T	G702D	1.000
3:62533058:C:G	G702R	1.000

dbSNP variants (sampled 300 via entrez): RS1000014076 (3:62836495 A>G), RS1000018175 (3:62398828 T>A), RS1000019406 (3:62509567 A>C), RS1000020397 (3:62871120 C>A,T), RS1000023063 (3:62477859 G>A), RS1000026559 (3:62754260 C>T), RS1000026983 (3:62519503 A>G), RS1000031046 (3:62681978 T>G), RS1000039258 (3:62744693 T>C), RS1000061918 (3:62609834 A>G), RS1000072623 (3:62797179 C>A), RS1000073373 (3:62487315 A>C), RS1000073594 (3:62791211 T>A), RS1000081093 (3:62430560 G>C), RS1000082091 (3:62804207 A>T)

Disease associations

OMIM: gene MIM:604667 | disease phenotypes:

GenCC curated gene-disease

Mondo (1): prostate cancer (MONDO:0008315)

Orphanet (1): Familial prostate cancer (Orphanet:1331)

HPO phenotypes

0 total (0 of 0 shown, HPO-id order):

GWAS associations

30 associations (top):

Study	Trait	p-value
GCST001512_4	Economic and political preferences (environmentalism)	6.000000e-06
GCST001585_28	Breast size	4.000000e-06
GCST002119_19	Metabolite levels (X-11787)	2.000000e-06
GCST003075_111	Cognitive decline rate in late mild cognitive impairment	3.000000e-10
GCST003075_94	Cognitive decline rate in late mild cognitive impairment	2.000000e-10
GCST003434_5	Obsessive-compulsive symptoms	5.000000e-06
GCST003985_23	Breast size	2.000000e-06
GCST004031_8	QT interval (sulfonylurea treatment interaction)	3.000000e-07
GCST005830_1	Hand grip strength	5.000000e-08
GCST006201_1	Thiopurine-induced leukopenia in inflammatory bowel disease	2.000000e-07
GCST006482_4	Lung function (FEV1/FVC)	2.000000e-08
GCST007323_86	Risk-taking tendency (4-domain principal component model)	7.000000e-10
GCST007556_29	Autism spectrum disorder	6.000000e-07
GCST008154_37	Trunk fat mass	8.000000e-06
GCST008758_62	Pre-treatment viral load in HIV-1 infection	6.000000e-18
GCST009462_47	Optic disc size	8.000000e-11
GCST009864_2	Fasting plasma glucose	2.000000e-12
GCST010132_10	Processed meat consumption	3.000000e-09
GCST010143_32	Meat-related diet	7.000000e-09
GCST010425_2	Systolic blood pressure x educational attainment (graduated college) interaction (2df)	3.000000e-10
GCST010698_51	Subcortical volume (min-P)	9.000000e-11
GCST010699_71	Brain morphology (min-P)	8.000000e-19
GCST010701_103	Cortical surface area (MOSTest)	2.000000e-12
GCST010702_121	Subcortical volume (MOSTest)	2.000000e-09
GCST010703_56	Brain morphology (MOSTest)	1.000000e-08
GCST010988_148	Adult body size	9.000000e-11
GCST010988_149	Adult body size	4.000000e-08
GCST010989_222	Body size at age 10	2.000000e-08
GCST011494_84	Daytime nap	4.000000e-08
GCST012180_4	Cigarettes smoked per day in Schizophrenia	5.000000e-07

EFO canonical traits (17, from GWAS)

EFO ID	Trait name
EFO:0004827	economic and social preference
EFO:0005276	hydroxy-leucine measurement
EFO:0007710	cognitive decline measurement
EFO:0007802	obsessive-compulsive symptom measurement
EFO:0004682	QT interval
EFO:0007922	response to sulfonylurea
EFO:0006941	grip strength measurement
EFO:0004713	FEV/FVC ratio
EFO:0008579	risk-taking behaviour
EFO:0010125	viral load
EFO:0008111	diet measurement
EFO:0004784	self reported educational attainment
EFO:0006335	systolic blood pressure
EFO:0004346	neuroimaging measurement
EFO:0009819	comparative body size at age 10, self-reported
EFO:0007828	daytime rest measurement
EFO:0006525	cigarettes per day measurement

MeSH disease descriptors (1)

Descriptor	Name	Tree numbers
D011471	Prostatic Neoplasms	C04.588.945.440.770; C12.100.500.260.750; C12.100.500.565.625; C12.200.294.260.750; C12.200.294.565.625; C12.200.758.409.750; C12.900.619.750

Drugs & pharmacology

Drug and pharmacology data

Is drug target: no

PharmGKB: 1 entry (VIP=true, CPIC=false)

CTD chemical–gene interactions

23 total (human), top 23 by PubMed support.

Chemical	Actions (top 5)	PubMed papers
Valproic Acid	affects cotreatment, decreases expression	4
methylmercuric chloride	decreases expression, increases expression	2
trichostatin A	decreases expression, increases expression	2
Vorinostat	affects cotreatment, increases expression	2
Tretinoin	increases expression	2
arsenite	increases methylation	1
aflatoxin B2	increases methylation	1
4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide	increases expression, affects cotreatment, decreases expression	1
dorsomorphin	affects cotreatment, decreases expression, increases expression	1
bisphenol S	decreases expression	1
NSC305787	decreases expression	1
Temozolomide	decreases expression	1
Sunitinib	decreases expression	1
Benzo(a)pyrene	affects methylation	1
Cadmium	decreases expression	1
Diethylhexyl Phthalate	decreases expression	1
Ivermectin	decreases expression	1
Latex	decreases expression	1
Lead	affects splicing	1
Phthalic Acids	increases methylation	1
Smoke	decreases expression	1
Triclosan	decreases expression	1
Aflatoxin B1	decreases methylation	1

Clinical trials (associated diseases)

300 trials via MONDO — disease-level, not drug-specific.

Trial	Phase	Status	Title
NCT00029224	PHASE4	COMPLETED	Treatment With Zoledronic Acid in Patients With Breast Cancer, Multiple Myeloma, and Prostate Cancer With Cancer Related Bone Lesions
NCT00035997	PHASE4	COMPLETED	Open-label Trial on the Effect of I.V. Zoledronic Acid 4 mg on Bone Density in Hormone Sensitive Prostate Cancer Patients With Bone Metastasis
NCT00063609	PHASE4	COMPLETED	The Effect of Zoledronic Acid on Bone Loss in Prostate Cancer Patients Undergoing Androgen Deprivation Therapy
NCT00103623	PHASE4	SUSPENDED	The Plenaxis® Experience Study
NCT00106392	PHASE4	COMPLETED	A Safety and Efficacy Study of Prograf in the Prevention of Erectile Dysfunction After Radical Prostatectomy
NCT00185029	PHASE4	UNKNOWN	MR-Lymphography and Lymph Node Staging in Prostate Cancer
NCT00199485	PHASE4	COMPLETED	Angelica Sinensis for the Treatment of Hot Flashes in Men Undergoing LHRH Therapy for Prostate Cancer
NCT00219219	PHASE4	COMPLETED	Zoledronic Acid in the Prevention of Skeletal-related Events in Hormone Refractory and Hormone-sensitive Prostate Cancer Patients With Bone Metastases
NCT00219271	PHASE4	COMPLETED	Effect Of Zoledronic Acid On Circulating And Bone Marrow-Residing Prostate Cancer Cells In Patients With Clinically Localized Prostate Cancer
NCT00237146	PHASE4	COMPLETED	Study to Evaluate Zoledronic Acid on Quality of Life and Skeletal-related Events as Adjuvant Treatment in Patients With Hormone-naïve Prostate Cancer and Bone Metastasis Who Have Undergone Orchiectomy
NCT00242554	PHASE4	COMPLETED	Open-label Phase IV Clinical Trial to Evaluate the Safety and Tolerability of Zoledronic Acid in Patients With Prostate Cancer and Bone Metastases
NCT00280098	PHASE4	COMPLETED	Docetaxel in the Treatment of Hormone Refractory Prostate Cancer
NCT00293696	PHASE4	COMPLETED	Casodex/Zoladex Biomarkers in Localised Prostate Cancer
NCT00334139	PHASE4	COMPLETED	Effect of Zoledronic Acid on Bone Metabolism in Patients With Bone Metastasis and Prostate or Breast Cancer
NCT00375765	PHASE4	COMPLETED	Effects On Dihydrotestosterone Regulated Gene Expression In Benign Prostatic Hyperplasia Or Prostate Cancer
NCT00391690	PHASE4	COMPLETED	Evaluation of Bone Markers as Diagnostic Tools for Early Detection of Bone Metastases in Patients With High Risk Prostate Cancer
NCT00422708	PHASE4	COMPLETED	Local Anesthesia for Prostate Biopsy
NCT00526331	PHASE4	COMPLETED	Evaluation of Arterial Pressure Based Cardiac Output for Goal-Directed Perioperative Therapy
NCT00590213	PHASE4	COMPLETED	Compare the Value of Prophylactic Versus Therapeutic Breast Radiotherapy in CASODEX
NCT00629330	PHASE4	TERMINATED	Dissemination of Prostate Cancer Screening to PCP’s in African American Communities
NCT00771966	PHASE4	COMPLETED	Radical Prostatectomy and Perioperative Fluid Therapy
NCT00805701	PHASE4	COMPLETED	Study Assessing The Efficacy And Safety Of Avodart (Dutasteride) At Improving Urinary Symptoms In Men With Prostate Cancer Who Are Undergoing Seed Implantation
NCT00859027	PHASE4	COMPLETED	Effect Of Risedronate On Bone Mass In Older Men Receiving Neoadjuvant Therapy For Prostate Cancer
NCT00906269	PHASE4	UNKNOWN	Can Hyperbaric Oxygen Improve Erectile Function Following Surgery for Prostate Cancer
NCT00953277	PHASE4	COMPLETED	Study of Nerve Reconstruction Using AVANCE in Subjects Who Undergo Robotic Assisted Prostatectomy for Treatment of Prostate Cancer
NCT00982800	PHASE4	COMPLETED	Does Postoperative Gabapentin Reduce Pain, Opioid Consumption and Anxiety and Have a Positive Effect on Health Related Quality of Life After Radical Prostatectomy?
NCT01083199	PHASE4	COMPLETED	Global Performance Evaluation of the AMS CONTINUUM™ Device
NCT01136226	PHASE4	COMPLETED	Evaluate Recovery of Testosterone for Patients Using Eligard
NCT01161563	PHASE4	COMPLETED	Randomized Crossover Trial to Assess the Tolerability of Gonadotropin Releasing Hormone (GnRH) Analogue Administration
NCT01230905	PHASE4	COMPLETED	Study to Monitor the Effects of Androgen Suppression Treatment on the Heart
NCT01296672	PHASE4	COMPLETED	3 Month Finasteride Challenge Test Can Significantly Improve the Performance of Screening for Prostate Cancer
NCT01365143	PHASE4	TERMINATED	Prospective Randomized Trial Comparing Robotic Versus Open Radical Prostatectomy
NCT01379742	PHASE4	UNKNOWN	Comparison of Between ThinSeed™ and OncoSeed™ for Permanent Prostate Brachytherapy
NCT01486563	PHASE4	COMPLETED	Hydroxyethyl Starch and Renal Function After Radical Prostatectomy
NCT01511874	PHASE4	COMPLETED	Efficacy and Safety Study of ELIGARD 22.5mg With Prostate Cancer
NCT01512472	PHASE4	TERMINATED	Firmagon (Degarelix) Intermittent Therapy
NCT01547416	PHASE4	COMPLETED	The Effect of Combined General/Epidural Anesthesia Versus General Anesthesia on Diaphragmatic Function
NCT01571544	PHASE4	COMPLETED	The Use of Thermal Suits as Preventing Hypothermia During Surgery
NCT01581749	PHASE4	UNKNOWN	Evaluation of Truebeam for Low-Intermediate Risk Prostate Cancer
NCT01649635	PHASE4	COMPLETED	Study of Cabazitaxel Combined With Prednisone and Prophylaxis of Neutropenia Complications in the Treatment of Patients With Metastatic Castration-resistant Prostate Cancer